TY - JOUR TI - Comparative immunohistochemical analysis of aurora-A and aurora-B expression in human glioblastomas. Associations with proliferative activity and clinicopathological features AU - Samaras, V. AU - Stamatelli, A. AU - Samaras, E. AU - Arnaoutoglou, C. AU - Arnaoutoglou, M. AU - Stergiou, I. AU - Konstantopoulou, P. AU - Varsos, V. AU - Karameris, A. AU - Barbatis, C. JO - PATHOLOGY RESEARCH AND PRACTICE PY - 2009 VL - 205 TODO - 11 SP - 765-773 PB - SN - 0344-0338 TODO - 10.1016/j.prp.2009.06.011 TODO - aurora A kinase; aurora B kinase; carmustine; Ki 67 antigen; temozolomide, adult; aged; antigen expression; article; cancer combination chemotherapy; cancer radiotherapy; cancer surgery; cancer survival; cell proliferation; clinical article; female; glioblastoma; histopathology; human; human tissue; immunohistochemistry; immunoreactivity; male; multiple cycle treatment; primary tumor; prognosis; protein function; survival time; tumor localization, Adult; Aged; Aged, 80 and over; Analysis of Variance; Brain Neoplasms; Cell Proliferation; Cerebral Cortex; Combined Modality Therapy; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meiers Estimate; Ki-67 Antigen; Male; Middle Aged; Protein-Serine-Threonine Kinases; Statistics, Nonparametric; Treatment Outcome TODO - In the present study, we carried out a comparative immunohistochemical analysis of aurora-A and aurora-B expression in 40 patients with primary glioblastomas, and attempted to identify any associations with Ki-67 index and the patients' clinical features. The impact of various treatment modalities and proliferative activity on patient outcome was also assessed. Immunohistochemistry was carried out using formalin-fixed and paraffin-embedded tissue sections. Aurora-A expression was higher in tumors with high Ki-67 expression (p=0.01) and was positively, though marginally, related to aurora-B expression (p=0.085). Aurora-B expression was not linked to Ki-67 expression (p=0.182). Lower aurora-A immunohistochemical expression, chemotherapy administration, and tumor localization in one lobe of the brain implied a greater probability of patient survival in univariate analysis (p=0.044, p=0.008, p=0.041, respectively). Ki-67 and aurora-B immunoreactivities were not associated with patient survival (p=0.918 and p=0.539, respectively). To our knowledge, for the first time, the association between aurora-A and aurora-B expression, the correlation of aurora-A with Ki-67 index, and the prognostic impact of aurora-A expression were assessed in glioblastomas. Although we addressed a prognostic connotation of aurora-A, we presume that aurora-A and aurora-B play a complicated role within glioblastomas. Further examinations of larger series are required, so that definite conclusions can be drawn. © 2009 Elsevier GmbH. All rights reserved. ER -